Innoviva, Inc. (INVA)
NASDAQ: INVA · IEX Real-Time Price · USD
15.26
+0.27 (1.80%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Innoviva Revenue
In the year 2023, Innoviva had annual revenue of $310.46M, a decrease of -6.30%. Revenue in the quarter ending December 31, 2023 was $85.84M with 30.45% year-over-year growth.
Revenue (ttm)
$310.46M
Revenue Growth
-6.30%
P/S Ratio
3.11
Revenue / Employee
$2,771,991
Employees
112
Market Cap
964.85M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 310.46M | -20.88M | -6.30% |
Dec 31, 2022 | 331.34M | -60.53M | -15.45% |
Dec 31, 2021 | 391.87M | 55.07M | 16.35% |
Dec 31, 2020 | 336.79M | 75.78M | 29.03% |
Dec 31, 2019 | 261.02M | 12.00K | 0.00% |
Dec 31, 2018 | 261.00M | 43.79M | 20.16% |
Dec 31, 2017 | 217.22M | 83.65M | 62.63% |
Dec 31, 2016 | 133.57M | 79.62M | 147.58% |
Dec 31, 2015 | 53.95M | 45.52M | 539.74% |
Dec 31, 2014 | 8.43M | 3.90M | 86.08% |
Dec 31, 2013 | 4.53M | -1.08M | -19.26% |
Dec 31, 2012 | 5.61M | -18.90M | -77.10% |
Dec 31, 2011 | 24.51M | 289.00K | 1.19% |
Dec 31, 2010 | 24.22M | -151.00K | -0.62% |
Dec 31, 2009 | 24.37M | 1.28M | 5.53% |
Dec 31, 2008 | 23.10M | 1.09M | 4.97% |
Dec 31, 2007 | 22.00M | 2.42M | 12.33% |
Dec 31, 2006 | 19.59M | 7.53M | 62.49% |
Dec 31, 2005 | 12.05M | 3.11M | 34.83% |
Dec 31, 2004 | 8.94M | 5.34M | 147.99% |
Dec 31, 2003 | 3.61M | 3.45M | 2,210.90% |
Dec 31, 2002 | 156.00K | - | - |
Dec 31, 2001 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alignment Healthcare | 1.82B |
BioCryst Pharmaceuticals | 331.41M |
MiMedx Group | 321.48M |
Standard BioTools | 106.34M |
Cronos Group | 87.24M |
Simulations Plus | 64.67M |
Bicycle Therapeutics | 26.98M |
Liquidia | 17.49M |
INVA News
- 3 days ago - Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 - Business Wire
- 7 weeks ago - Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 2 months ago - Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - 10 stocks you can bet on being inflation-proof - Market Watch
- 6 months ago - Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress - Business Wire
- 6 months ago - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea - Business Wire
- 7 months ago - Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023 - Business Wire
- 7 months ago - Innoviva to Participate in the Cantor Global Healthcare Conference - Business Wire